SNP communications: coalition of toxicology and drug metabolism and pharmacokinetics.
Ikeda
Toshihiko
T
D000818:Animals; D001711:Biotransformation / Q000187:drug effects*; D056486:Chemical and Drug Induced Liver Injury; D002839:Chromans / Q000009:adverse effects / Q000493:pharmacokinetics; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics*; D004798:Enzymes / Q000235:genetics; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D008658:Inactivation, Metabolic / Q000235:genetics; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008107:Liver Diseases / Q000378:metabolism; D026901:Membrane Transport Proteins / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods*; D010599:Pharmacokinetics; D020641:Polymorphism, Single Nucleotide; D045162:Thiazolidinediones / Q000009:adverse effects / Q000493:pharmacokinetics; D000077288:Troglitazone
D002839:Chromans; D004798:Enzymes; D015395:Histocompatibility Antigens Class I; D007004:Hypoglycemic Agents; D026901:Membrane Transport Proteins; D045162:Thiazolidinediones; D000077288:Troglitazone